Takeda (4502) Q2 2026 earnings review
Takeda raises its profit plan, but underlying drug sales shrink
Takeda, the Japanese drugmaker, lifted its full-year profit and cash flow plans as cost cuts and a weak yen outweighed a slower quarter for its biggest medicines. Second-quarter revenue rose 7% to 1,187 billion yen on currency tailwinds, but constant-currency sales fell 2% as established brands stalled. Even so, Core operating profit (excluding one-offs) climbed 11%, and chief executive Julie Kim added two newly approved medicines, ORZEYFUL and MIMRYLO, to the commercial portfolio. By our math, the raised full-year outlook still leaves second-half Core operating profit down 10% as launch spending ramps up.
| Q2 constant-currency revenue | -1.6% -0.5% in Q1 (Reported Q2: +6.7% to JPY 1,187.1B) |
|---|---|
| Q2 Core operating profit (excluding one-offs) | JPY 351.7B +10.8% from a year ago (+1.9% at constant currency) |
| Core In-line Brands H1 growth (constant currency) | +0.5% +2.3% in Q1 (58% of total revenue) |
| Full-year Core operating profit outlook | Raised JPY 30B CER upgraded to mid-single-digit % decline (from -5% to -8%) |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because higher cost savings and new drug approvals were offset by a slowdown in Takeda's established portfolio. Upgrading the constant-currency profit plan shows the cost transformation is ahead of schedule, and paying off $1.5 billion in bonds lowered leverage to 2.5 times adjusted earnings. One caution: Core In-line Brands slowed to 0.5% constant-currency growth in the first half from 2.3% in the first quarter, and the 172% jump in reported net profit came mostly from one-off tax benefits and lower write-downs.
The question now is whether the three new flagship launches will generate net growth or merely refill a hole from aging medicines and US price pressure on gut drug ENTYVIO. If established brands hold steady, the new medicines will lift total sales starting next year; if key brands keep slowing, top-line revenue will stay flat. Management's peak-sales targets at the December 11, 2026 Capital Markets Day and third-quarter brand growth will tell.
🐂 Bull Case
Profit Outlook Raised on Cost Discipline
Takeda, the Japanese drugmaker, is cutting overhead to pay for new medicine launches under a two-stage plan it calls Horizon One and Horizon Two. In the second quarter, Core operating profit (which excludes one-offs and intangible write-downs) rose 10.8% to 351.7 billion yen, or 1.9% at constant exchange rates, as gross margin expanded 1.1 percentage points.
- Cost of making products: 33.0% of revenue in Q2, down 1.1 percentage points from a year ago
- Selling and administrative costs: down 1.1% at constant exchange rates in Q2
- Full-year restructuring budget: 160 billion yen, trimmed from 170 billion yen
Because first-half costs stayed flat in constant currency, Takeda lifted its full-year Core operating profit forecast by 30 billion yen to 1,190 billion yen. At constant exchange rates, the drugmaker now plans for a mid-single-digit percentage drop instead of the 5% to 8% fall it projected in May. However, the outlook still leaves second-half Core operating profit falling 10.1% by our math, because management plans "accelerated investment supporting new product launches, mainly for zasocitinib".
What to watch: selling and administrative expenses in the third quarter. A continued drop at constant currency would show that cost savings from the ”ongoing implementation of the transformation program” are offsetting the new marketing spend.
Two New Medicines Win Regulatory Approval
Chief executive Julie Kim is counting on three late-stage medicines to return Takeda to growth once patent losses fade. This quarter, the company added ORZEYFUL (its narcolepsy treatment oveporexton) and MIMRYLO (its blood-cancer drug rusfertide) to its New Launches category as recently approved products. Meanwhile, the group is speeding up commercial preparations for zasocitinib, its oral psoriasis pill.
Takeda also raised research and development spending by 10.9% in the first half to 338.6 billion yen (up 2.1% at constant exchange rates) to fund late-stage trials for follow-on drugs arcotatug tavatecan (TAK-921), elritercept (TAK-226) and TAK-928. Moving two flagship drugs from the laboratory into the commercial portfolio reduces regulatory risk, even though new medicines take two to three years to add to profit.
What to watch: long-term peak sales targets at the Capital Markets Day in Tokyo on December 11, 2026. Specific revenue figures for ORZEYFUL, MIMRYLO and zasocitinib will show whether the new cohort can outgrow upcoming patent expirations.
Debt Paydown Lowers Leverage Ratio
Instead of buying back shares, the Tokyo-based company is using cash to pay down debt toward a medium-term leverage target of 2.0 times adjusted earnings. On September 23, 2026, Takeda redeemed $1.5 billion of senior notes at maturity, cutting total bonds and loans by 306.2 billion yen over six months to 4,575.6 billion yen.
That debt reduction, alongside a 10.5% rise in first-half Adjusted EBITDA (earnings before interest, tax, depreciation and amortization, excluding one-offs), lowered net debt to 2.5 times Adjusted EBITDA from 2.6 times in March and 2.7 times in June. However, a new building lease in Cambridge, Massachusetts added 193.0 billion yen to other financial liabilities and pushed first-half Core net finance costs up 18.8% to 79.8 billion yen.
What to watch: net debt to Adjusted EBITDA at fiscal year-end in March 2027. A drop toward 2.3 times as second-half cash flow arrives would keep the balance sheet on track for the 2.0 times goal.
🐻 Bear Case
Established Brands Stalled and Pulled Sales Down
While reported second-quarter revenue grew 6.7% to 1,187.1 billion yen on ”foreign exchange impacts from the depreciation of the Japanese yen”, sales at constant exchange rates fell 1.6%. That constant-currency drop worsened from a 0.5% dip in the first quarter because ”a decline in revenue from loss of exclusivity-impacted and mature products” outweighed newer brands.
- Core In-line Brands (58% of revenue): up 0.5% at constant currency in H1, down from 2.3% in Q1
- New Launches (4% of revenue): up 17.3% at constant currency in H1, down from 22.6% in Q1
- US revenue: down 5.4% at constant currency in H1
- Plasma-Derived Therapies (blood-plasma treatments): down 1.5% at constant currency in H1, with albumin down 6.9%
This slowdown matters because Takeda's biggest medicines are losing momentum before the new launches generate meaningful sales. ENTYVIO, its flagship gut-inflammation drug making up 22.5% of revenue, grew 2.7% at constant currency in the first half despite ”continued growth in patient numbers, supported by increased use of the subcutaneous formulation”, slowing from 3.8% in the first quarter. By our math, that means Core In-line Brands shrank in the second quarter alone.
What to watch: constant-currency growth for Core In-line Brands in the third quarter. Another near-zero reading would mean new launches must first replace shrinking established products before Takeda can grow overall.
Reported Profit Surge Rests on Accounting
Takeda's headline net profit attributable to owners jumped 171.8% in the first half to 305.6 billion yen, and second-quarter net profit reached 192.4 billion yen against a 11.8 billion yen loss a year ago. However, underlying profit barely moved: first-half Core net profit slipped 0.2% at constant exchange rates, and Core earnings per share fell 1.2%.
Three non-operating or non-cash items drove the headline jump. First, Takeda finished amortizing intangible assets for its attention-deficit drug VYVANSE and lapped last year's 58.2 billion yen cell-therapy write-off, cutting second-quarter intangible charges by 9.4 percentage points of revenue by our math. Second, the company booked a 36.5 billion yen tax benefit in the quarter from a ”reassessment of the recoverability of deferred tax assets” and subsidiary restructuring. Excluding that 68.2 billion yen one-off tax adjustment, second-quarter reported net profit was 124.2 billion yen by our math.
What to watch: second-half reported operating profit. By our math, the full-year forecast of 453.0 billion yen leaves just 46.3 billion yen for the second half because Takeda budgets 100 billion yen for full-year intangible write-offs and 160 billion yen for restructuring.
Risks This Quarter Didn't Answer
Four standing concerns received no new data in the first-half earnings release and financial appendix.
- Launch commercial terms: Takeda added ORZEYFUL and MIMRYLO to its New Launches bucket but did not disclose US pricing, insurance coverage or initial patient uptake.
- AMITIZA antitrust appeal: current provisions stayed elevated at 962.1 billion yen (including the 402.5 billion yen jury-verdict provision from May), with no update on appeal timing.
- US drug-pricing rules: the release gave no update on Medicare price negotiations for ENTYVIO from 2028 or potential US tariff and pricing policies.
- Restructuring disruption: Takeda booked 52.4 billion yen more in first-half restructuring charges, but gave no headcount update on the planned 4,500 role reductions.
👓 Other Themes
Weak Yen Carries Full-Year Revenue Raise
Takeda raised its full-year reported and Core revenue forecast by 60 billion yen (1.3%) to 4,700 billion yen while keeping its constant-currency outlook at a low-single-digit percentage decline. Management updated its full-year currency assumptions to 158 yen per US dollar (from 156 yen) and 23.5 yen per Chinese yuan (from 22.4 yen), meaning exchange rates explain the entire top-line increase.
💲 Other KPIs
Free cash flow (operating cash flow minus property and equipment purchases) rebounded to 259.6 billion yen in Q2 by our math, up from 73.8 billion yen in Q1, though still down 23.2% from a year ago. For the first half, Adjusted free cash flow (which also deducts intangible asset purchases of 60.5 billion yen) fell 38.0% to 325.7 billion yen on higher trade receivables.
Sales in Gastroenterology (gut-health medicines, Takeda's largest unit) rose 12.1% in the first half, or 2.5% at constant exchange rates, slowing from 3.1% constant-currency growth in Q1. By our math, Q2 division sales rose 10.5% to 390.7 billion yen, led by ENTYVIO at 273.4 billion yen (+10.9%) and acid-reflux drug TAKECAB/VOCINTI.
Neuroscience sales grew 7.2% in the first half, but fell 1.6% at constant exchange rates as generic copies of VYVANSE continued to erode US sales. That constant-currency drop narrowed from a 4.8% decline in Q1 because antidepressant TRINTELLIX grew 15.6% at constant currency in the first half on higher US prices and an easier comparison.
🔮 Guidance
Raised on currency, unchanged at constant exchange rates. The plan lifts full-year revenue by 60 billion yen to 4.3% reported growth while keeping constant-currency sales at a low-single-digit drop. By our math, that leaves second-half revenue at 2,293.0 billion yen, up 0.3% from a year ago after 8.4% growth in the first half.
Raised. Takeda lifted its forecast by 30 billion yen (to +1.5% reported growth) and upgraded its constant-currency plan to a mid-single-digit decline. By our math, that leaves 479.4 billion yen for the second half, down 10.1% from a year ago as launch spending for zasocitinib ramps up. Takeda beat its final full-year Core operating profit target by an average of 1.5% over the past two years.
Raised. The drugmaker added 10 yen to its Core earnings per share target (now -6.8% reported by our math) and improved its constant-currency forecast from a mid-teens drop to a low-teens drop. By our math, after earning 308 yen in the first half, the plan leaves 174 yen for the second half, down 26.9% from a year ago.
Raised. The forecast rose by 33 billion yen (+7.9%), helped by lower expected restructuring costs of 160 billion yen (down from 170 billion yen). Because Takeda already earned 406.7 billion yen in the first half, the plan leaves 46.3 billion yen for the second half by our math, as it keeps a 100 billion yen full-year allowance for intangible write-offs.
Raised. Net profit attributable to owners moved up 43 billion yen (+25.9%) as deferred tax benefits lowered the expected full-year effective tax rate to about 23%. Because first-half net profit already reached 305.6 billion yen, the full-year target implies a reported net loss of 96.6 billion yen in the second half by our math.
Raised. The middle of the range moved up 50 billion yen to 750 billion yen (+9.6% vs last year by our math), while capital expenditure plans stayed at 330 to 380 billion yen. After generating 325.7 billion yen in the first half, Takeda needs 424.3 billion yen in the second half to reach the middle of the range.
❓ Key Questions
Why did Core In-line Brands stall in the second quarter?
Constant-currency growth for Core In-line Brands slowed from 2.3% in Q1 to 0.5% for the first half, implying a Q2 contraction by our math. How much of that slowdown came from US price pressure on ENTYVIO versus lower albumin sales in the US and China?
What are the initial launch metrics for ORZEYFUL and MIMRYLO?
Both medicines joined the New Launches bucket as recently approved products this quarter, yet New Launches growth slowed from 22.6% in Q1 to 17.3% in H1. When will US commercial shipments begin, and what first-year revenue is inside the raised outlook?
How much launch spending is shifting into the second half?
Even after the 30 billion yen raise, the full-year outlook implies second-half Core operating profit will drop 10.1% and margin will fall to 20.9% by our math. How much of that step-down is dedicated to zasocitinib launch preparation versus normal seasonal expenses?
What drives the 424 billion yen second-half cash flow rebound?
Takeda raised its Adjusted free cash flow target by 50 billion yen despite first-half cash flow falling 38% to 325.7 billion yen. Will trade receivables reverse in the second half, and how much of the Protagonist Therapeutics opt-out payment remains to be paid?